Greenwich LifeSciences, Inc.
GLSI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001799788
In the last 90 days, Greenwich LifeSciences, Inc. insiders filed 3 open-market purchases and 0 sales; 57 institutions reported holding it in 13F filings for Q2 2026, worth $39.6M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $97.0K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 57
- 13F valueReported value at the end of Q2 2026
- $39.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GLSI, Q2 2026
No superinvestor reported holding GLSI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Greenwich LifeSciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 (view filing)6:05 AM ET | Jul 28-29 | 2 days | Patel SnehalCEO and CFO | PPurchase | +2.20K | $13.43 | +$29.6K | 0.0%5.61M after | 2 lots |
| Jul 29, 2026 (view filing)6:05 AM ET | Jul 27 | 2 days | Patel SnehalCEO and CFO | PPurchase | +1.50K | $13.62 | +$20.4K | 0.0%5.61M after | |
| Jul 27, 2026 (view filing)6:15 AM ET | Jul 23-24 | 4 days | Patel SnehalCEO and CFO | PPurchase | +3.60K | $13.06 | +$47.0K | +0.1%5.61M after | 2 lots |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Patel SnehalCEO and CFO | PPurchase | +1.80K | $29.83 | +$53.7K | 0.0%5.60M after | |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Patel SnehalCEO and CFO | PPurchase | +2.90K | $27.54 | +$79.9K | +0.1%5.60M after | |
| Jan 5, 2026 (view filing) | Dec 31, 2025 | 5 days | Patel SnehalCEO and CFO | PPurchase | +4.30K | $21.36 | +$91.8K | +0.1%5.60M after | |
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Patel SnehalCEO and CFO | PPurchase | +2.90K | $21.73 | +$63.0K | +0.1%5.60M after | |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Patel SnehalCEO and CFO | PPurchase | +4.10K | $12.62 | +$51.7K | +0.1%5.59M after | |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Patel SnehalCEO and CFO | PPurchase | +4.60K | $8.37 | +$38.5K | +0.1%5.59M after | |
| Nov 12, 2025 (view filing) | Nov 7 | 5 days | Patel SnehalCEO and CFO | PPurchase | +10.6K | $8.43 | +$89.4K | +0.2%5.58M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Greenwich LifeSciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 485,854 | $11.4M | 0.00% | +51,994+12.0% | Added |
| Vanguard Capital Management LLC | 278,190 | $6.53M | 0.00% | −20,076−6.7% | Reduced |
| Geode Capital Management, LLC | 168,179 | $3.95M | 0.00% | +12,713+8.2% | Added |
| State Street Corp | 143,086 | $3.36M | 0.00% | +9,211+6.9% | Added |
| Vanguard Portfolio Management LLC | 80,861 | $1.90M | 0.00% | +21,950+37.3% | Added |
| Northern Trust Corp | 80,228 | $1.88M | 0.00% | +5,103+6.8% | Added |
| Bank of New York Mellon Corp | 47,900 | $1.12M | 0.00% | +1,377+3.0% | Added |
| Vanguard Fiduciary Trust Co | 45,965 | $1.08M | 0.00% | +1,057+2.4% | Added |
| Morgan Stanley | 43,447 | $1.02M | 0.00% | +13,620+45.7% | Added |
| Goldman Sachs Group Inc | 39,329 | $922.7K | 0.00% | −192−0.5% | Reduced |